VIDEO: Study examines trastuzumab deruxtecan in first line for breast cancer subset
Click Here to Manage Email Alerts
In a video interview, Sara M. Tolaney, MD, MPH, discussed the currently enrolling DESTINY-Breast09 trial presented at the virtual ESMO Congress.
The randomized phase 3 trial is looking at whether trastuzumab deruxtecan (Enhertu; Daiichi Sankyo, AstraZeneca), with or without pertuzumab, would be better than the standard-of-care regimen in metastatic HER2-positive breast cancer, according to Tolaney, associate director of the Susan F. Smith Center for Women's Cancers, director of breast oncology clinical trials and director of breast immunotherapy clinical research at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School.
Given the “remarkable data” from DESTINY-Breast03, which demonstrated the efficacy of trastuzumab deruxtecan in the second-line setting, DESTINY-Breast09 is looking at its efficacy in the first line and will utilize three treatment arms (trastuzumab deruxtecan plus placebo; trastuzumab deruxtecan plus pertuzumab; and a taxane, trastuzumab and pertuzumab [THP]).
“I think we’re all very hopeful that we may see that [trastuzumab deruxtecan] potentially can be better than our current standard of care and hopefully will continue to improve outcomes for our patients with metastatic HER2-positive breast cancer,” Tolaney said.
Collapse
Tolaney SM, et al. Abstract 328TiP. Presented at: European Society for Medical Oncology Congress (virtual meeting); Sept. 16-21, 2021.
Click Here to Manage Email Alerts